Inventor · disambiguated record
Edna Mozes
Also filed as: MOZES EDNA
7 granted patents·3 pending applications·93 citations·filing 1990–2018
84Inventor score
Top patents by PatentIndex Score
10 records- 0180US5556754AMethods for assessing the ability of a candidate drug to suppress MHC class I expressionUS ARMY·Filed 1995·Granted Sep 17, 1996·54 cites·17 claims
- 0274US7858738B2Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosusYEDA RES & DEV·Filed 2007·Granted Dec 28, 2010·2 cites·22 claims
- 0349US6066621ASynthetic peptides for the treatment of myasthenia gravisYEDA RES & DEV·Filed 1995·Granted May 23, 2000·9 cites·37 claims
- 0446US5356779AAssay for direct binding of peptides that are T-cell epitopes to MHC gene products on intact antigen-presenting cells and the use thereof for screening susceptibility of autoimmune diseasesYEDA RES & DEV·Filed 1990·Granted Oct 18, 1994·14 cites·7 claims
- 0546US2010322928A1Methods of diagnosing, monitoring treatment and treating systemic lupus erythematosus (sle)YEDA RES & DEV·Filed 2008·Application pending·0 cites
- 0645US2004235729A1Synthethic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosusYEDA RES & DEV·Filed 2003·Application pending·0 cites
- 0743US2004127408A1Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosusFiled 2002·Application pending·0 cites
- 0842US11167005B2Peptides for treating Sjogren's syndromeYEDA RES & DEV·Filed 2018·Granted Nov 9, 2021·0 cites·11 claims
- 0940US6613536B1Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosusYEDA RES & DEV·Filed 1996·Granted Sep 2, 2003·9 cites·28 claims
- 1040US5871950AMethods of treating autoimmune diseases and transplantation rejectionFiled 1995·Granted Feb 16, 1999·5 cites·5 claims
Join the waitlist — get patent alerts
Get an alert when Edna Mozes files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →